The perils of inhibiting deficient factors
- PMID: 29883037
- DOI: 10.1111/jth.14195
The perils of inhibiting deficient factors
Abstract
Essentials Anticoagulation in patients with factor X deficiency is an evidence-poor area. A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban. Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency. A baseline coagulation screen should be performed prior to commencement of anticoagulation.
Summary: We report a case of a previously undiagnosed factor X deficiency in an 83-year-old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.
Keywords: coagulation; factor X; oral anticaogulants; pharmacotherapeutics; rivaroxaban.
© 2018 International Society on Thrombosis and Haemostasis.
LinkOut - more resources
Full Text Sources
Other Literature Sources